Mandelson Unveils Plans For New Drug Development Campus
Stevenage, Hertfordshire - October 13, 2009
Plans for a unique £37m Bioscience Campus in Stevenage, Hertfordshire, funded in partnership by the Government, GlaxoSmithKline, The Wellcome Trust, Technology Strategy Board and East of England Development Agency, will be announced by Business, Innovation and Skills Secretary, Lord Mandelson.
The project aims to create a hub for early-stage biotech companies, operating under a model of open-innovation and collaboration. The Campus will offer each company access to specialist skills, equipment and expertise, to help stimulate innovation in drug development.
The Stevenage Campus represents a huge investment in the future of Britain’s bioscience industry and is a strong new platform for the work of our Office for Life Sciences. It will leverage our existing strengths as a world leader in the sector, helping it to grow and reinforcing our international competitiveness. And ultimately it will help us build towards a stronger UK economy coming out of the global downturn," said Lord Mandelson at the Technology Strategy Board’s Innovate09 Conference.
It’s estimated that development of the campus could create up to 1,500 new jobs, most of which will be high-skilled. It will initially be home to around 25 companies, co-located with GlaxoSmithKline on its existing research site, with plans to increase capacity at the park fivefold over the next 10 years.
"EEDA has been working with GSK for the last 18 months to develop and secure funding for the UK’s first open innovation campus for drug discovery and development. Today’s announcement strengthens the region’s position as a world leader in life sciences, it will create thousands of new jobs and enable us to compete on the global stage. It’s a great example of how regional interventions can stimulate projects of national significance with a global outreach," said Richard Ellis, Chair from East of England Development Agency.
The Campus is being part-funded with £11.7m from the UK Strategic Investment Fund. The £750m fund was established in Budget ’09 as part of the Government’s New Industry, New Jobs strategy to position the economy for the global upturn by supporting projects in fields where the UK has comparative strengths. The UK Strategic Investment Fund – Interim Report has been published, setting out the principles behind the fund and the investment commitments that have been made so far.
Total investment in the Campus stands at around £37.6m. On top of the £11.7 SIF funding for the project, GlaxoSmithKline has granted £10.9m; The Wellcome Trust has committed £6m; the Technology Strategy Board is providing £5m and EEDA will look to contribute £4m.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
